Skip to main content
Top
Published in: Infection 2/2024

Open Access 13-09-2023 | SARS-CoV-2 | Research

Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort

Authors: Pierantonio Grimaldi, Antonio Russo, Mariantonietta Pisaturo, Paolo Maggi, Enrico Allegorico, Ivan Gentile, Vincenzo Sangiovanni, Annamaria Rossomando, Rossella Pacilio, Giosuele Calabria, Raffaella Pisapia, Canio Carriero, Alfonso Masullo, Elio Manzillo, Grazia Russo, Roberto Parrella, Giuseppina Dell’Aquila, Michele Gambardella, Antonio Ponticiello, Lorenzo Onorato, Nicola Coppola, CoviCam group

Published in: Infection | Issue 2/2024

Login to get access

Abstract

Introduction

The aim of this study was to investigate how long hospitalized patients stayed positive to the nasopharyngeal swab, and what demographic and clinical factors influence the time-to-negative swab.

Methods

We enrolled in a multicenter, observational, retrospective study involving 17 COVID-19 units in eight cities of the Campania, southern Italy all patients hospitalized from March 2020 to May 2021 diagnosed with Severe Acute Respiratory Distress Syndrome-Coronavirus-2 (SARS-CoV-2) infection for whom time-to-negative swab was available.

Results

963 patients were enrolled. We defined three groups considering time-to-negative swab: the first including patients with time-to-negative swab before the 26th day, the second including patients with time-to-negative swab from day 26 to day 39, and the third including patients with time-to-negative swab > 39 days. 721 (74.9%) patients belonged to the first group, 194 (20.1%) to the second, and 52 (5.4%) belonged to the third group. Belonging to group 2 and 3 seemed to be influenced by age (p value < 0.001), Charlson comorbidity index (p = 0.009), arterial hypertension (p = 0.02), cardiovascular disease (p = 0.017), or chronic kidney disease (CKD) (p = 0.001). The multivariable analysis confers a leading role to CKD, with an odds ratio of 2.3 as factor influencing belonging to the groups showing a longer time-to-negative swab. Patients with CKD and diabetes were more frequently in the third group.

Discussion

Our analysis showed that CKD is a factor related to longer time-to-negative swab, probably because of immunosuppression related to this condition.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO. WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization; 2021. WHO. WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization; 2021.
2.
go back to reference Centre for Disease Prevention E. Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19-first update Scope of this document. 2020. Centre for Disease Prevention E. Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19-first update Scope of this document. 2020.
4.
go back to reference Tagarro A, Sanz-Santaeufemia FJ, Grasa C, Cobos E, Yebra J, Alonso-Cadenas JA, Baquero-Artigao F, Mesa-Guzmán JM, Pérez-Seoane B, Calvo C, Herreros ML, Epalza C, Melendo S, Dominguez-Rodriguez S, Vidal P, Pacheco M, Ballesteros A, Bernardino M, Villanueva-Medina S, Rodríguez-Molino P, Miragaya Castro S, Rivière J, Garcés R, Santiago B, Fumadó V, Urretavizcaya-Martínez M, García-García ML, Penín M, Cava F, Sáez E, Iglesias-Bouzas MI, Herrero B, de Reinoso T, J, Moraleda C,. Dynamics of reverse transcription-polymerase chain reaction and serologic test results in children with SARS-CoV-2 infection. J Pediatr. 2022;241:126-132.e3. https://doi.org/10.1016/J.JPEDS.2021.09.029.CrossRefPubMed Tagarro A, Sanz-Santaeufemia FJ, Grasa C, Cobos E, Yebra J, Alonso-Cadenas JA, Baquero-Artigao F, Mesa-Guzmán JM, Pérez-Seoane B, Calvo C, Herreros ML, Epalza C, Melendo S, Dominguez-Rodriguez S, Vidal P, Pacheco M, Ballesteros A, Bernardino M, Villanueva-Medina S, Rodríguez-Molino P, Miragaya Castro S, Rivière J, Garcés R, Santiago B, Fumadó V, Urretavizcaya-Martínez M, García-García ML, Penín M, Cava F, Sáez E, Iglesias-Bouzas MI, Herrero B, de Reinoso T, J, Moraleda C,. Dynamics of reverse transcription-polymerase chain reaction and serologic test results in children with SARS-CoV-2 infection. J Pediatr. 2022;241:126-132.e3. https://​doi.​org/​10.​1016/​J.​JPEDS.​2021.​09.​029.CrossRefPubMed
6.
go back to reference Cento V, Colagrossi L, Nava A, Lamberti A, Senatore S, Travi G, Rossotti R, Vecchi M, Casati O, Matarazzo E, Bielli A, Casalicchio G, Antonello M, Renica S, Costabile V, Scaglione F, Fumagalli R, Ughi N, Epis OM, Puoti M, Vismara C, Faccini M, Fanti D, Alteri C, Perno CF. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020;81:e90–2. https://doi.org/10.1016/J.JINF.2020.06.024].CrossRefPubMedPubMedCentral Cento V, Colagrossi L, Nava A, Lamberti A, Senatore S, Travi G, Rossotti R, Vecchi M, Casati O, Matarazzo E, Bielli A, Casalicchio G, Antonello M, Renica S, Costabile V, Scaglione F, Fumagalli R, Ughi N, Epis OM, Puoti M, Vismara C, Faccini M, Fanti D, Alteri C, Perno CF. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020;81:e90–2. https://​doi.​org/​10.​1016/​J.​JINF.​2020.​06.​024].CrossRefPubMedPubMedCentral
7.
9.
go back to reference Gliga S, Lübke N, Killer A, Gruell H, Walker A, Dilthey AT, Thielen A, Lohr C, Flaßhove C, Krieg S, Pereira JV, Seraphin TP, Zaufel A, Däumer M, Orth H-M, Feldt T, Bode JG, Klein F, Timm J, Luedde T, Jensen B-EO. Rapid selection of sotrovimab escape variants in severe acute respiratory syndrome coronavirus 2 omicron-infected immunocompromised patients. Clin Infect Dis. 2023;76:408–15. https://doi.org/10.1093/CID/CIAC802].CrossRefPubMed Gliga S, Lübke N, Killer A, Gruell H, Walker A, Dilthey AT, Thielen A, Lohr C, Flaßhove C, Krieg S, Pereira JV, Seraphin TP, Zaufel A, Däumer M, Orth H-M, Feldt T, Bode JG, Klein F, Timm J, Luedde T, Jensen B-EO. Rapid selection of sotrovimab escape variants in severe acute respiratory syndrome coronavirus 2 omicron-infected immunocompromised patients. Clin Infect Dis. 2023;76:408–15. https://​doi.​org/​10.​1093/​CID/​CIAC802].CrossRefPubMed
11.
go back to reference Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabié A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustillères F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, Yordanov Y. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. Clin Microbiol Infect. 2023. https://doi.org/10.1016/j.cmi.2022.12.016).CrossRefPubMed Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabié A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustillères F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, Yordanov Y. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. Clin Microbiol Infect. 2023. https://​doi.​org/​10.​1016/​j.​cmi.​2022.​12.​016).CrossRefPubMed
12.
go back to reference Pisaturo M, Russo A, Pattapola V, Astorri R, Maggi P, Numis FG, Gentile I, Sangiovanni V, Rossomando A, Gentile V, Calabria G, Pisapia R, Codella AV, Masullo A, Iodice V, Giolitto G, Parrella R, Dell’Aquila G, Gambardella M, Di Perna F, Coppola N, CoviCam Group. clinical characterization of the three waves of COVID-19 occurring in Southern Italy: results of a multicenter cohort study. Int J Environ Res Public Health. 2022;19:16003. https://doi.org/10.3390/ijerph192316003.CrossRefPubMedPubMedCentral Pisaturo M, Russo A, Pattapola V, Astorri R, Maggi P, Numis FG, Gentile I, Sangiovanni V, Rossomando A, Gentile V, Calabria G, Pisapia R, Codella AV, Masullo A, Iodice V, Giolitto G, Parrella R, Dell’Aquila G, Gambardella M, Di Perna F, Coppola N, CoviCam Group. clinical characterization of the three waves of COVID-19 occurring in Southern Italy: results of a multicenter cohort study. Int J Environ Res Public Health. 2022;19:16003. https://​doi.​org/​10.​3390/​ijerph192316003.CrossRefPubMedPubMedCentral
14.
go back to reference Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, Sangiovanni V, Esposito V, Punzi R, Calabria G, Rescigno C, SalomoneMegna A, Masullo A, Manzillo E, Russo G, Parrella R, Dell’Aquila G, Gambardella M, Ponticiello A, Coppola N, On Behalf Of CoviCam Group. Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19-an observational retrospective study. Pathogens. 2022;11:652. https://doi.org/10.3390/pathogens11060652.CrossRefPubMedPubMedCentral Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, Sangiovanni V, Esposito V, Punzi R, Calabria G, Rescigno C, SalomoneMegna A, Masullo A, Manzillo E, Russo G, Parrella R, Dell’Aquila G, Gambardella M, Ponticiello A, Coppola N, On Behalf Of CoviCam Group. Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19-an observational retrospective study. Pathogens. 2022;11:652. https://​doi.​org/​10.​3390/​pathogens1106065​2.CrossRefPubMedPubMedCentral
16.
go back to reference StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC; 2019. StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC; 2019.
17.
go back to reference Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, Aguayo-Hiraldo P, Pinsky BA, Pekosz A, Shen L, Boyd SD, Wirz OF, Röltgen K, Bootwalla M, Maglinte DT, Ostrow D, Ruble D, Han JH, Biegel JA, Li M, Huang C, Sahoo MK, Pannaraj PS, O’Gorman M, Judkins AR, Gai X, Dien BJ. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. EBioMedicine. 2021;67:1355. https://doi.org/10.1016/j.ebiom.2021.103355.CrossRef Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, Aguayo-Hiraldo P, Pinsky BA, Pekosz A, Shen L, Boyd SD, Wirz OF, Röltgen K, Bootwalla M, Maglinte DT, Ostrow D, Ruble D, Han JH, Biegel JA, Li M, Huang C, Sahoo MK, Pannaraj PS, O’Gorman M, Judkins AR, Gai X, Dien BJ. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. EBioMedicine. 2021;67:1355. https://​doi.​org/​10.​1016/​j.​ebiom.​2021.​103355.CrossRef
18.
go back to reference Batra A, Clark JR, Kang AK, Ali S, Patel TR, Shlobin NA, Hoffman SC, Lim PH, Orban ZS, Visvabharathy L, Graham EL, Sullivan DP, Muller WA, Chou SH, Ungvári Z, Koralnik IJ, Liotta EM. Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patients. Geroscience. 2022;44:1241–54. https://doi.org/10.1007/s11357-022-00561-z.CrossRefPubMedPubMedCentral Batra A, Clark JR, Kang AK, Ali S, Patel TR, Shlobin NA, Hoffman SC, Lim PH, Orban ZS, Visvabharathy L, Graham EL, Sullivan DP, Muller WA, Chou SH, Ungvári Z, Koralnik IJ, Liotta EM. Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patients. Geroscience. 2022;44:1241–54. https://​doi.​org/​10.​1007/​s11357-022-00561-z.CrossRefPubMedPubMedCentral
20.
go back to reference Baldi F, Dentone C, Mikulska M, Fenoglio D, Mirabella M, Magnè F, Portunato F, Altosole T, Sepulcri C, Giacobbe DR, Uras C, Scavone G, Taramasso L, Orsi A, Cittadini G, Filaci G, Bassetti M. Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. Front Med (Lausanne). 2023;9:1062450. https://doi.org/10.3389/fmed.2022.1062450.CrossRefPubMed Baldi F, Dentone C, Mikulska M, Fenoglio D, Mirabella M, Magnè F, Portunato F, Altosole T, Sepulcri C, Giacobbe DR, Uras C, Scavone G, Taramasso L, Orsi A, Cittadini G, Filaci G, Bassetti M. Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. Front Med (Lausanne). 2023;9:1062450. https://​doi.​org/​10.​3389/​fmed.​2022.​1062450.CrossRefPubMed
21.
go back to reference Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a b cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir/ritonavir. Clin Infect Dis. 2023;76:926–9. https://doi.org/10.1093/cid/ciac868.CrossRefPubMed Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a b cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir/ritonavir. Clin Infect Dis. 2023;76:926–9. https://​doi.​org/​10.​1093/​cid/​ciac868.CrossRefPubMed
22.
go back to reference Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, Labate L, Russo C, Mirabella M, Magnasco L, Di Grazia C, Ghiggi C, Raiola AM, Giacobbe DR, Vena A, Beltramini S, Bruzzone B, Lemoli RM, Angelucci E, Bassetti M. Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients. Clin Infect Dis. 2023. https://doi.org/10.1093/cid/ciad181.CrossRefPubMed Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, Labate L, Russo C, Mirabella M, Magnasco L, Di Grazia C, Ghiggi C, Raiola AM, Giacobbe DR, Vena A, Beltramini S, Bruzzone B, Lemoli RM, Angelucci E, Bassetti M. Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients. Clin Infect Dis. 2023. https://​doi.​org/​10.​1093/​cid/​ciad181.CrossRefPubMed
23.
go back to reference Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, Li Y, Ni Q, Zou R, Li X, Xu M, Zhang Y, Zhao H, Zhang X, Yu L, Su J, Lang G, Liu J, Wu X, Guo Y, Tao J, Shi D, Yu L, Cao Q, Ruan B, Liu L, Wang Z, Xu Y, Liu Y, Sheng J, Li L. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;71:799–806. https://doi.org/10.1093/cid/ciaa351.CrossRefPubMed Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, Li Y, Ni Q, Zou R, Li X, Xu M, Zhang Y, Zhao H, Zhang X, Yu L, Su J, Lang G, Liu J, Wu X, Guo Y, Tao J, Shi D, Yu L, Cao Q, Ruan B, Liu L, Wang Z, Xu Y, Liu Y, Sheng J, Li L. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;71:799–806. https://​doi.​org/​10.​1093/​cid/​ciaa351.CrossRefPubMed
25.
go back to reference Li R, Jin C, Zhang L, Kong D, Hu K, Xuan M, Liu Q, Li S, Zhang K, Xue Y. Clinical characteristics and risk factors analysis of viral shedding time in mildly symptomatic and asymptomatic patients with SARS-CoV-2 Omicron variant infection in Shanghai. Front Public Health. 2023;4:1073387. https://doi.org/10.3389/fpubh.2022.1073387.CrossRef Li R, Jin C, Zhang L, Kong D, Hu K, Xuan M, Liu Q, Li S, Zhang K, Xue Y. Clinical characteristics and risk factors analysis of viral shedding time in mildly symptomatic and asymptomatic patients with SARS-CoV-2 Omicron variant infection in Shanghai. Front Public Health. 2023;4:1073387. https://​doi.​org/​10.​3389/​fpubh.​2022.​1073387.CrossRef
28.
go back to reference Moeinzadeh F, Raeisi V, Babahajiani M, Mortazavi M, Pourajam S, Seirafian S, Shirzadi M, Taheri S, Salahi M, Mansourian M, Toghyani A, Zamani Z. Is chronic kidney disease, a predictor of in-hospital mortality in coronavirus disease 2019 (COVID-19) patients? Adv Biomed Res. 2023;25:39. https://doi.org/10.4103/abr.abr_352_21.CrossRef Moeinzadeh F, Raeisi V, Babahajiani M, Mortazavi M, Pourajam S, Seirafian S, Shirzadi M, Taheri S, Salahi M, Mansourian M, Toghyani A, Zamani Z. Is chronic kidney disease, a predictor of in-hospital mortality in coronavirus disease 2019 (COVID-19) patients? Adv Biomed Res. 2023;25:39. https://​doi.​org/​10.​4103/​abr.​abr_​352_​21.CrossRef
29.
go back to reference Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE, STOP-COVID Investigators. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77:190-203.e1. https://doi.org/10.1053/j.ajkd.2020.09.003.CrossRefPubMed Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE, STOP-COVID Investigators. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77:190-203.e1. https://​doi.​org/​10.​1053/​j.​ajkd.​2020.​09.​003.CrossRefPubMed
Metadata
Title
Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort
Authors
Pierantonio Grimaldi
Antonio Russo
Mariantonietta Pisaturo
Paolo Maggi
Enrico Allegorico
Ivan Gentile
Vincenzo Sangiovanni
Annamaria Rossomando
Rossella Pacilio
Giosuele Calabria
Raffaella Pisapia
Canio Carriero
Alfonso Masullo
Elio Manzillo
Grazia Russo
Roberto Parrella
Giuseppina Dell’Aquila
Michele Gambardella
Antonio Ponticiello
Lorenzo Onorato
Nicola Coppola
CoviCam group
Publication date
13-09-2023
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-023-02095-8

Other articles of this Issue 2/2024

Infection 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.